Efficacy and safety of fezakinumab (an anti-IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments - A randomized, double-blind, phase 2a trial.

Author
:
E Guttman-Yassky
PM Brunner
AU Neumann
S Khattri
AB Pavel
K Malik
GK Singer
D Baum
P Gilleaudeau
M Sullivan-Whalen
S Rose
Jim On
X Li
J Fuentes-Duculan
Y Estrada
S Garcet
C Traidl-Hoffmann
JG Krueger
MG Lebwohl
Abstract
:

IL-22 promotes epidermal hyperplasia and inhibits skin barrier function.
Year of Publication
:
2018
Journal
:
Journal of the American Academy of Dermatology
Date Published
:
2018
ISSN Number
:
0190-9622
URL
:
http://linkinghub.elsevier.com/retrieve/pii/S0190-9622(18)30101-4
DOI
:
10.1016/j.jaad.2018.01.016
Short Title
:
J Am Acad Dermatol
Download citation